Latest news with #XPro
Motor Trend
6 days ago
- Automotive
- Motor Trend
2026 Kia Sportage First Drive: Comfy and Cool—But Quick Enough?
Kia messed with a good thing. Just three short years into its current form, the Sportage gets refreshed for 2026 with updated cosmetics and newer tech, among other changes. It's reliably been a strong contender in our Ultimate Car Rankings, so we drove the updated Sportage to see if it's still worthy—yes, but its main shortcoming remains. The 2026 Kia Sportage refresh features updated styling, enhanced tech, and improved driver assists but its base engine is still a sluggish 2.5L four-cylinder. Despite its slow acceleration, the X-Pro we drove offers a smooth ride, impressive build quality, and good value. This summary was generated by AI using content from this MotorTrend article Read Next Updates to the 2026 Kia Sportage This generation of Sportage went on sale for 2023 with weird but cool styling; sculpted bodywork and swoopy lighting shapes add visual personality that prosaic compact SUVs often lack. That somewhat alien aesthetic is toned down for 2026, as the Sportage now wears LED-accented headlights with a vertical theme. These give it a relatively upright, SUV-ish appearance that better aligns with other Kia SUV models. Beyond new wheel styles and paint colors, other exterior design changes include subtle adjustments to the taillights and lower bumpers. Inside, the 12.3-inch infotainment touchscreen once reserved for higher trims becomes standard, but more important it runs a new user interface. Called CCNC ('Connected Car Navigation Cockpit' in Kia parlance), it has higher processing power, a revised menu structure, and greater over-the-air update capability. It's embedded in a restyled dashboard that, like the exterior, trades some funky shapes for relatively plain straight-line trim. In the driver assist suite, front and rear parking sensors become standard, the adaptive cruise control is refined, and the lane keep system is paired with a capacitive touch sensor in the new two-spoke steering wheel. Our review here focuses on the standard all-gas Sportage, which remains powered by the same engine as before. However, the Sportage Hybrid and Plug-In Hybrid gain more power—you can read about updates to those models here. Still Slow If Kia had changed anything about the Sportage for 2026, we wish it was that gas engine: a 2.5-liter I-4 producing 187 hp and 178 lb-ft of torque, joined to an eight-speed automatic with standard FWD or available AWD. It's slow—in MotorTrend testing, a 2023 Sportage X-Pro just like we have for 2026 needed 9.3 seconds to get to 60 mph from a stop. But is it too slow? Usually not. In normal driving, the engine doesn't feel like it's working hard, simply getting on with its business and keeping pace with traffic just fine. Ask for more, though, and it's gutless. Pedal down, the engine needs time to gather itself, eventually producing more noise than urgency. The Sportage isn't defined by its lethargy, but it's a factor—just forget about zipping around corners, jumping into gaps in traffic, or winning lane-merge drag races. The transmission tries to help by readily downshifting to make power available, yet the general lack of power undermines that effort. Still, shifts are smooth, lending a fluid sensation to driving. The only transmission oddity is when it occasionally lurches pulling away from a stop, a quirk more common in dual-clutch gearboxes than the torque converter unit found here. Fuel economy should come in at about 23–24/26–30 mpg city/highway with AWD, somewhat low among the Sportage's competitive set. Note as well that the Sportage Hybrid and Plug-In Hybrid are not only more fuel efficient but also considerably quicker. Otherwise, Smooth Beyond its lack of speed, the Sportage leaves very little to complain about—rather, it provides plenty to enjoy. The ride quality is supremely comfortable, verging on luxurious. With tall, supple all-terrain tires adding cushion between the cabin and road, the high-end X-Pro model we evaluated likely rides the best of any Sportage. Still, it uses the same basic suspension as other versions, so every 2026 Sportage should have a similarly plush feel that soaks up road imperfections nicely. Handling perhaps suffers due to the soft suspension, as the body rebounds and wobbles in reaction. The Sportage feels mostly stable, but it's clearly not meant to cut up a road, as if the meager power didn't make that obvious. How the steering and brakes are tuned aligns with this relaxed demeanor. Sporty the Sportage isn't, so just cruise and relish the smoothness. How's CCNC? Kia's previous user interface left some to be desired, and CCNC makes improvements in key areas. This evolution of the previous menu structure remains mostly intuitive, but the entire system is finished with graphics that look more modern and improve clarity. Touch responsiveness is quicker, though still a blink behind newer smartphones. Wireless Apple CarPlay and Android Auto are standard. More reconfigurability in the digital gauge cluster would be nice, which hopefully could arrive in a future over-the-air update among other improvements. A 12.3-inch touchscreen isn't particularly big among today's affordable crossovers, but it's a good size: legible and useful but not so large that it seems shoved into the cabin. Below that, the slightly clumsy touch-sensitive multifunction climate and media control panel remains. Kia's driver assist features continue to make highway driving easier, aiding collaboratively to keep things steady. Having a capacitive steering wheel sensor for the lane keep assist is a nice upgrade, even if that system needs a fair amount of human management. Might Be Underpriced Fully loaded at about $42,000, this Sportage X-Pro comes across as a tremendously good deal. The amount of equipment—ventilated seats, panoramic sunroof, premium audio, 360-degree camera, and more—for that price is quite impressive. (As a point of reference, the 2026 Sportage starts a hair over $30,000.) But more impressive still is the degree of quality throughout the Sportage, in this trim or any other. It feels remarkably well-made, every touchpoint actuating with nice tactility and all surfaces joined in a tight, solid way. Thick sealing around the doors and windows secures the cabin against outside sounds. It all feels substantial, not something that can be said about every compact SUV. That shows up in how it drives, too. Its cushy ride is no accident, and even if the rest of the experience is a bit dull, there's refined cohesion in how it comes together. A humdrum engine is only one aspect of the Sportage, as its value, comfort, tech, and useful layout otherwise promote it as a good choice for an everyday SUV. The updated Sportage seems competent as ever as it enters 2026.
Yahoo
03-07-2025
- Business
- Yahoo
XPro Air Duct Cleaning Expands Indoor Air Quality and Dryer Safety Services Across the Chicago Metropolitan Area
Chicago, Illinois, July 03, 2025 (GLOBE NEWSWIRE) -- XPro Air Duct Cleaning & Dryer Vent Cleaning, a locally operated provider of HVAC maintenance services, announced today the expansion of its indoor air quality and dryer safety offerings throughout the Chicago metropolitan area. The expanded service coverage aims to help homeowners and businesses reduce fire hazards, improve system efficiency, and enhance indoor air conditions with accessible, flat-rate Air Duct Cleaning Elevates Indoor Air Quality and Dryer Safety Across Chicago Specializing in air duct cleaning, dryer vent cleaning, dryer pipe replacement, and vent cover upgrades, XPro is uniquely positioned to serve residential and commercial clients who value health, safety, and HVAC system efficiency. Their Chicago-based team has earned high ratings for its transparent service model and no-surprise pricing. Preventing Fire Hazards and Improving Air Quality According to the National Fire Protection Association, failure to clean dryer vents is one of the leading causes of house fires in the United States. Dirty air ducts also contribute to poor air circulation and can worsen respiratory conditions, especially for individuals with allergies or asthma. XPro's professional cleanings help reduce these risks by restoring ventilation systems to safe, optimal operation. 'Our focus is on delivering results that protect families and businesses,' said John Pery, spokesperson for XPro. 'It's not just about cleanliness. It's about improving air quality, reducing fire risk, and increasing system performance—while offering honest pricing our clients can trust.' Trusted, Local, and Reviewed XPro Air Duct Cleaning is a dedicated provider—not a generalist cleaning company—making it a standout choice in a competitive market. The company is fully licensed and exclusively focused on air duct and dryer vent services. With more than 60 ratings on Google Local Services and over 130 verified online reviews, the company has quickly gained traction for its customer satisfaction and service quality. Every client receives a free estimate, helping eliminate uncertainty and ensuring that services are aligned with real needs and budget expectations. Optimized for Local Search Visibility As more customers search for essential home services online, XPro's digital strategy is designed to align with Google's local search behavior. Instead of targeting high-competition keywords, XPro optimizes for medium-difficulty phrases that reflect real buyer intent, including: air duct cleaning near me dryer vent cleaning Chicago vent cleaning cost HVAC duct cleaning $99 air duct cleaning By targeting keywords with geographic and transactional intent, XPro strengthens both its Google search rankings and local map visibility, helping potential customers find and choose their services faster. Core Services Air Duct Cleaning – Removes dust, allergens, and debris for better airflow and indoor air quality Dryer Vent Cleaning – Clears hazardous lint buildup to reduce fire risk and improve efficiency Dryer Pipe Replacement – Replaces damaged or outdated dryer ductwork Vent Cover Replacement – Updates worn or broken vent covers for a cleaner and more functional system These services are especially important in older homes, apartment buildings, and multi-unit properties common in the greater Chicago area. Affordable Pricing with No Surprises XPro Air Duct Cleaning is known for its fair, flat-rate pricing and promotional packages. One of the company's most popular offers is its $99 maintenance air duct cleaning service, designed to make home maintenance affordable without sacrificing professionalism or results. By focusing on essential services at accessible rates, the company attracts both first-time homeowners and experienced property managers looking for long-term maintenance partners. Service Coverage XPro serves the entire Chicago metropolitan area, including downtown Chicago, North Side, South Side, and surrounding suburbs. The team is equipped to handle both urgent cleanings and routine maintenance projects, with flexible scheduling and responsive support. Popular service-related search terms include: dryer vent cleaning near me air duct cleaning services duct cleaning in Chicago vent cleaning professionals HVAC vent maintenance Areas Served Across Greater Chicago XPro Air Duct Cleaning & Dryer Vent Cleaning proudly serves a wide range of communities throughout the Greater Chicago area. Whether in the heart of the city or the surrounding suburbs, the company ensures fast response times and consistent service quality across all locations. Popular service areas include: Downtown Chicago North Side neighborhoods such as Lincoln Park, Lakeview, Uptown, Rogers Park, and Edgewater South Side communities like Hyde Park, Bronzeville, South Shore, and Beverly West Side areas including Austin, Humboldt Park, and Garfield Park Northwest Side suburbs such as Skokie, Niles, Park Ridge, and Des Plaines North Shore suburbs like Evanston, Wilmette, Winnetka, and Glencoe Western suburbs including Oak Park, Berwyn, Cicero, Elmhurst, and Hinsdale Southwest suburbs like Orland Park, Tinley Park, Oak Lawn, and Palos Hills Far western and southern suburbs such as Naperville, Aurora, Joliet, and Homewood By offering services across these diverse regions, XPro ensures that residents and business owners searching for 'air duct cleaning in Evanston,' 'dryer vent service in Oak Park,' or 'HVAC vent cleaning near Tinley Park' can find reliable, local expertise. To view full coverage or request service in your area, visit or call +1 (872) 873-2949. About XPro Air Duct Cleaning XPro Air Duct Cleaning & Dryer Vent Cleaning is a professional cleaning service based in Chicago, Illinois. The company is focused exclusively on air duct and dryer vent maintenance, offering fast, reliable service and transparent pricing. Known for its customer-first approach and extensive local experience, XPro is committed to helping Chicago residents and businesses breathe easier and stay safer. Business Name: XPro Air Duct Cleaning & Dryer Vent CleaningWebsite: +1 (872) 873-2949Service Area: Greater Chicago, IllinoisFree Estimates Available For media inquiries or to request a quote, contact:John PeryPhone: +1 (872) 873-2949Email: info@ XPro Air Duct Cleaning Elevates Indoor Air Quality and Dryer Safety Across Chicago
Bloomberg
01-07-2025
- Business
- Bloomberg
A Drug-Trial Stock Sale
Here's a weird little trade, first reported by Adam Feuerstein of StatNews. INmune Bio Inc. is a biotechnology company working on treatments for cancer and Alzheimer's Disease. It recently conducted a Phase 2 trial of an Alzheimer's drug called XPro. It ... didn't work, is the short summary (' showing no effects in the modified intent-to-treat population'), though there is some good news ('predefined analyses demonstrated a cognitive benefit for XPro over placebo on the primary endpoint'), and I do not want to give you any investing or medical advice. But INmune got these results last week, and it seems safe to say they were not what it was hoping for. As a small biotech company, INmune is not exactly awash in cash. As of March, it had about $19 million of cash and was spending about $3 million a month. A little more money might be nice, and for a small biotech company the way to get a little more money is to sell stock. Ideally the way to do this would be (1) get good trial results, (2) announce those results, (3) stock goes up, (4) sell stock into that demand. That option was not available, because the trial results were bad.
The Drive
01-07-2025
- Automotive
- The Drive
2026 Kia Telluride Goes Boxier in New Spy Shots
The latest car news, reviews, and features. It seems like not long ago that we welcomed the mid-cycle refresh of Kia's three-row family SUV, but in the brutal world of automotive product cycles, that was an entire lifetime ago. Kia's next-generation replacement is already deep in development, and production-ready bodies have already been spotted in the wild, doing SUV things. These prototypes appear to be undergoing hot-weather durability testing, making sure the car's powertrain cooling systems are up to everyday tasks—and then some. There's still extensive vinyl wrap on these prototypes, but we can see that Kia chose to lean into the boxier design we saw on the updated first-generation model. That overhaul brought with it a more chiseled nose and the entire X-Pro aesthetic, which has proven successful for Kia despite its mild functional upgrades. Judging by the grille and tire selections on display, we're looking at two or three trim grades here. There appear to be at least two configurations wearing knobby, off-road-adjacent tires (one with the rectangular mesh grille; the other with the white wheel 'accents' and vertical grille orientation). We suspect one is the X-Line, which leans more toward looks, while the other is the full-blown X-Pro. We don't know specifics of what Kia has in store for the next-gen Telluride, but we have a pretty compelling crib sheet in recently redesigned Hyundai Palisade, which rides on the same platform and utilizes the same powertrains. Hyundai's new SUV will offer a hybrid powertrain for the first time, along with the returning V6. Those trailers in the gallery below aren't foils; the new Palisade hybrid can tow 4,000 pounds, and we have every reason to suspect the Telluride will keep pace. 2026 isn't far away, so we expect to see the new Telluride in the metal sooner rather than later. For now, you can check out these prototypes by swiping or clicking through the full gallery below. Spot something weird in the wild? Let us know at tips@
Yahoo
30-06-2025
- Business
- Yahoo
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints. Treatment with XPro™ was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients. The most common adverse events (AE) were injection site reactions. Additional analyses will be presented at Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-31, 2025) and the Company will submit for Breakthrough Therapy designation with the FDA. Conference call today at 8AM ET, details below. Boca Raton, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), today announced results from its Phase 2 MINDFuL trial (NCT05318976) evaluating XPro™, a selective soluble TNF inhibitor, in early AD with biomarkers of inflammation. Despite showing no effects in the modified intent-to-treat population (mITT, n=200), predefined analyses demonstrated a cognitive benefit for XPro™ over placebo on the primary endpoint EMACC, a behavioral benefit on the Neuropsychiatric Inventory, and a biological benefit on pTau217 in early Alzheimer's patients with two or more biomarkers of inflammation at baseline (n=100), marking a key milestone in the development of XPro™ for Early AD. The MINDFuL trial, a double-blind, placebo-controlled study, enrolled 208 participants with early-stage AD to assess XPro™'s potential in slowing cognitive decline by tackling neuroinflammation. Patients with at least one of four inflammatory biomarkers (elevated CRP, ESR, HbA1c, or at least one ApoE4 allele) were randomized 2:1 (XPro™:placebo) and treated over 24 weeks. The primary endpoint was change in cognition over 6 months on the Early Mild Alzheimer's Cognitive Composite (EMACC), a cognitive assessment designed specifically to measure change in early AD patients. While the primary endpoint was not met in the mITT group, key changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of patients treated with XPro™ over patients treated with placebo. These results identify a clear population of AD patients for which XPro™ might have therapeutic benefit. Key Findings in the Amyloid positive Early AD participants with two or more biomarkers of inflammation (N=100): Cognition: A clinical benefit of XPro™ over placebo was observed on the primary endpoint EMACC (effect size: 0.27) and on the secondary endpoint Neuropsychiatric Inventory (effect size: -0.24). Alzheimer's Disease Biomarkers: A biological benefit of XPro™ over placebo was observed in blood levels of pTau217 (effect size: -0.20), the gold standard measure of AD pathology in blood. Safety and tolerability: XPro™ treatment was safe and well tolerated, without any occurrences of ARIA-E or ARIA-H. Injection site reactions (ISR) were common (80% of XPro™ group compared to placebo group (<20%). ISRs were short-term redness and/or pain at the injection site in two thirds of cases. Of the 14 patients in the XPro™ arm that discontinued the trial, ISR was the cause in 10 patients. There were no deaths, drug-related hospitalizations or organ system toxicity in the trial. Novel mechanism of action: This study demonstrates that it is possible to safely target neuroinflammation in patients where neuroinflammation is a driver of AD pathology. With the increased interest in inflammation as a disease-modifier in AD and neurodegeneration, these results provide the basis for further development of XPro™ in neurodegeneration. 'These results highlight the potential of XPro™,' stated RJ Tesi, MD, CEO of INmune Bio. 'Our findings indicate that XPro™ may offer benefits to Alzheimer's patients across all age groups, regardless of comorbidities, additional medications, or ApoE4 status. This evidence lays the foundation for advancing XPro™ as a promising treatment option for Alzheimer's disease.' CJ Barnum, PhD, VP of CNS Drug Development, added, 'By targeting neuroinflammation, a key driver of Alzheimer's disease progression, XPro™ offers a novel mechanism to potentially slow disease progression and cognitive symptoms for persons living with Alzheimer's disease and inflammation. The continued development of this therapeutic, whether as a standalone treatment or in combination with other therapies, holds promise in addressing this critical and growing unmet medical need.' Additional analyses are underway and will be presented at AAIC in Toronto, Canada (July 27-31, 2025). Expert Commentary on Use of Effect Size in Clinical Trials 'In early-phase Alzheimer's disease trials, absolute effect sizes of 0.2 or greater are considered preliminary evidence of potential therapeutic efficacy and are informative for signal detection in early phase studies when sample sizes are small and the unknowns of a novel mechanism are significant,' said Dr. Judith Jaeger, a leading expert in cognitive assessment and consultant to INmune Bio on this trial. 'When a therapy consistently meets the 0.2 benchmark across multiple parameters (clinical and biological), confidence in the validity of the observed effects increases, indicating a therapy is worth advancing.' Next Steps INmune Bio will present additional analyses from the MINDFuL trial at AAIC® in Toronto, Canada (July 27-31, 2025). Based on the totality of the data, the company intends to: File for Breakthrough Therapy Designation with the FDA. Schedule an End-of-Phase 2 meeting with the FDA in Q4 2025 to define the path for a pivotal trial to support XPro™ approval in early AD. Engage regulatory authorities in the UK, EU, and other regions in parallel. MINDFuL Results Call Information: To participate in this event, dial approximately at least 10 minutes before the beginning of the call or use the webcast link below. Please ask for the INmune Bio MINDFuL Conference Call when reaching the operator. Date: June 30, 2025Time: 8:00 AM Eastern TimeParticipant Dial-in: +1-800-267-6316 Participant Dial-in (international): +1-203-518-9783Conference ID: INMUNE NOTE: THIS CONFERENCE ID WILL BE REQUIRED FOR ENTRY To join by webcast link please click here or copy and past the link below into your browser: A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through July 30, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering pin no. 11159260. Acknowledgements INmune Bio wishes to extend their gratitude to the participants, caregivers, trial site staff, vendors, and any others who supported the efforts of this proof-of-concept phase 2 clinical trial. About MINDFuL (NCT05318976) The MINDFuL trial is an international, blinded, randomized Phase 2 trial in patients with Early AD with biomarkers of elevated neuroinflammation. Early AD includes patients with MCI (mild cognitive impairment) and mild AD. Patients must have at least one of four biomarkers of inflammation – elevated CRP, HgbA1c, ESR or ApoE4 allele. Patients receive either XPro™ or placebo (2:1 ratio) for 6 months. The cognitive endpoints are EMACC and CDR. XPro™ is given as a once-a-week subcutaneous injection. For more information on the MINDFuL clinical trial please visit or About Judith Jaeger, PhD Judith Jaeger, PhD, is the principal developer of the EMACC. Judith Jaeger PhD is founder and President of CognitionMetrics, a prominent neurocognition consulting firm. Dr. Jaeger is an internationally recognized expert in designing cognitive function testing programs to use in clinical trials with more than two decades' experience. About EMACC The EMACC is a validated cognitive composite derived from six standardized neuropsychological tests, empirically developed to provide optimal for sensitivity to decline in early AD. Unlike traditional clinical rating scales, EMACC minimizes variance from informant demographics, providing an objective measure of cognitive performance with no floor or ceiling effects. About XPro™ XPro™ is an advanced tumor necrosis factor (TNF) inhibitor that targets soluble TNF (sTNF) while preserving trans-membrane TNF (tmTNF) and TNF receptors. By reducing neuroinflammation, XPro™ may offer significant benefits for patients with neurologic disorders, potentially enhancing cognitive function and supporting neuronal communication. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary allogeneic, pooled, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio's product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. Forward Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. Company Contact: David Moss Chief Financial Officer (561) 710-0512info@ Daniel Carlson Head of Investor Relations (415) 509-4590dcarlson@ in to access your portfolio
